Aristotle Funds, an investment advisor, released its “Growth Equity Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. equity markets reached new all-time ...
DexCom (NasdaqGS:DXCM) is seeing higher adoption of its continuous glucose monitoring systems among patients using GLP-1 drugs, as physicians pair both therapies for diabetes care. The company is ...
Study Confirms Safety of Using Theranica’s Nerivio REN Wearable for Treatment of Migraine Simultaneously with Contemporary Continuous Glucose Monitoring (CGM) Devices Published in the Journal of ...
Theranica, a neuromodulation therapeutics company advancing clinically validated, drug-free treatments for idiopathic pain conditions and setting a new standard of care in migraine with REN-based ...
On February 13, Mizuho analyst Anthony Petrone raised the price target on DexCom, Inc. (NASDAQ: DXCM) to $90 from $78 while maintaining an Outperform rating, citing a favorable post-earnings setup ...
DexCom, Inc. (NASDAQ:DXCM) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 13, William Plovanic from Canaccord Genuity reduced the price target on DexCom ...
Leach succeeds Abbott EVP of Diabetes Care, Chris Scoggins, in the position. Eric Benjamin, Insulet’s EVP and COO, will serve as the vice chair for the medical device industry association’s Diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results